http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H10316561-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06627dd34699551c2502bc83e25c24bf |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-15 |
| filingDate | 1997-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37d5f9894660cdd7ef8ab9038b3a1b27 |
| publicationDate | 1998-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H10316561-A |
| titleOfInvention | New anticancer drugs and their adjustment methods |
| abstract | (57) [Summary] [Problem] Focusing on the fact that cancer cells are abnormally dividing more frequently than normal cells, hydrazine is used to reduce the oxygen concentration required for the division of cancer cells. Suppress growth. Hydrazine concentration should be kept as low as possible so as not to interfere with normal cell division. SOLUTION: Hydrazine is diluted with physiological saline, and the dilution ratio is estimated using graph 1 to estimate the minimum concentration that inhibits the division of cancer cells and the maximum concentration that normal cells can divide. |
| priorityDate | 1997-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 17.